Related references
Note: Only part of the references are listed.PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
Juan M. Roldan-Romero et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility
Martin Kobel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2019)
Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm
Ying-Bei Chen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma
Jozefina Casuscelli et al.
EUROPEAN UROLOGY FOCUS (2019)
Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations?
Megan Parilla et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations Molecular Analysis Supports an Expanding Clinicopathologic Spectrum
Doreen N. Palsgrove et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus
Pablo Maroto et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma
Raj K. Gopal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Christopher J. Ricketts et al.
CELL REPORTS (2018)
High-grade oncocytic renal tumor: morphologic, immunohistochemical, and molecular genetic study of 14 cases
Huiying He et al.
VIRCHOWS ARCHIV (2018)
Kidney cancer characteristics and genotype-phenotype-correlations in Birt-Hogg-Dube syndrome
Elke C. Sattler et al.
PLOS ONE (2018)
Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors
Andrew Dhawan et al.
NATURE COMMUNICATIONS (2018)
Heteroplasmic shifts in tumor mitochondrial genomes reveal tissue-specific signals of relaxed and positive selection
Sneha Grandhi et al.
HUMAN MOLECULAR GENETICS (2017)
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Jozefina Casuscelli et al.
JCI INSIGHT (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J. Kwiatkowski et al.
CLINICAL CANCER RESEARCH (2016)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2016)
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Martin H. Voss et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Renal Cell Carcinoma in Tuberous Sclerosis Complex
Ping Yang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Tuberous Sclerosis–associated Renal Cell Carcinoma
Juan Guo et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Caleb F. Davis et al.
CANCER CELL (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer
Brian Shuch et al.
JOURNAL OF UROLOGY (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Chromophobe renal cell carcinoma: A review of an uncommon entity
Francisco Emilio Vera-Badillo et al.
INTERNATIONAL JOURNAL OF UROLOGY (2012)
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
Anna Yemelyanova et al.
MODERN PATHOLOGY (2011)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
